ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Creative Diagnostics Announces Respiratory Syncytial Virus Animal Models to Advance RSV Research

Creative Diagnostics Announces Respiratory Syncytial Virus Animal Models to Advance RSV Research
Creative Diagnostics launches advanced Respiratory Syncytial Virus Animal Models for researchers and scientists worldwide.

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the launch of its advanced Respiratory Syncytial Virus Animal Models for researchers and scientists worldwide focused on advancing RSV research and accelerating the development of effective vaccines and therapeutics against RSV.

Human respiratory syncytial virus (hRSV) is an enveloped, single-stranded, negative-sense RNA virus that represents a significant public health burden in both developing and developed countries. Scientists have made concerted efforts to develop various animal models to study different aspects of hRSV. However, the high specificity of hRSV for the human host has greatly hindered the development of specialized animal models. In addition, because no single animal model reflects all aspects of this viral infection and disease, a variety of models have been used to study RSV, ranging from rodents and small mammals to large animals and non-human primates (NHPs).

With the exception of chimpanzees, nonhuman primates are only partially susceptible to hRSV replication. After infection, nonhuman primates have mild or no clinical signs and generally show mild lung lesions. Cotton rats, mice, ferrets, chinchillas, guinea pigs, hamsters, and newborn lambs are also not susceptible to RSV infection. Additionally, cotton rats and mice have been invaluable in the development of monoclonal antibody prophylaxis for high-risk infants and have provided insights into RSV immunity and pathogenesis.

RSV animal models are important tools for studying the complex dynamics of RSV infection, evaluating potential therapies, and developing effective vaccines. With advanced animal modeling technology and unparalleled infectious disease expertise, Creative Diagnostics provides researchers and scientists with reliable respiratory syncytial virus animal models to facilitate the development of therapies and vaccines. Its team of experts can provide clients with the most appropriate RSV animal model based on the infection to be studied and the proposed research hypothesis.

Creative Diagnostics offers a full range of services to support RSV animal model research, including study design and execution, pathological analysis and immune response profiling, as well as in vivo pharmacokinetic studies and pharmacodynamics/efficacy/toxicity assessments. These RSV animal model services allow scientists to evaluate the immunogenicity and efficacy of potential RSV vaccine candidates in preclinical studies, investigate RSV pathogenesis to identify novel therapeutic targets, and assess the safety and efficacy of antiviral and immunomodulatory compounds.

With extensive expertise in biological research, Creative Diagnostics offers RSV Cotton Rat Models and RSV Mouse Models to advance RSV research, vaccine development, and drug discovery. By providing RSV animal models, Creative Diagnostics aims to help accelerate the development of effective treatments and improve patient outcomes. With this new offering, Creative Diagnostics reinforces its commitment to providing high-quality research tools and services to advance the understanding and treatment of infectious diseases.

For more information on the RSV animal models, please visit https://antiviral.creative-diagnostics.com/respiratory-syncytial-virus-animal-model.html.

About Creative Diagnostics

Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.

Media Contact
Company Name: Creative Diagnostics
Contact Person: Thomas Schmitt
Email: Send Email
State: New York
Country: United States
Website: https://antiviral.creative-diagnostics.com/


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.